NASDAQ:INO - Inovio Pharmaceuticals Stock Price, Forecast & News

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Inovio Pharmaceuticals shares reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

Inovio Pharmaceuticals Inc (NASDAQ:INO) issued its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.01. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to analyst estimates of $2.72 million. Inovio Pharmaceuticals had a negative net margin of 1,809.64% and a negative return on equity of 179.91%. During the same period last year, the firm earned ($0.27) earnings per share. View Inovio Pharmaceuticals' Earnings History.

Inovio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Inovio Pharmaceuticals.

7 Wall Street analysts have issued 12-month price targets for Inovio Pharmaceuticals' stock. Their forecasts range from $3.62 to $13.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $7.80 in the next year. This suggests a possible upside of 76.5% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals.

News headlines about INO stock have been trending extremely negative on Friday, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inovio Pharmaceuticals earned a coverage optimism score of -4.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Inovio Pharmaceuticals.

Inovio Pharmaceuticals saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 12,300,000 shares, an increase of 23.5% from the January 30th total of 9,960,000 shares. Based on an average trading volume of 4,070,000 shares, the days-to-cover ratio is presently 3.0 days. Approximately 12.6% of the shares of the company are short sold. View Inovio Pharmaceuticals' Current Options Chain.

Some companies that are related to Inovio Pharmaceuticals include AtriCure (ATRC), Silk Road Medical (SILK), Cardiovascular Systems (CSII), Atrion (ATRI), Shockwave Medical (SWAV), Luminex (LMNX), Axonics Modulation Technologies (AXNX), Tactile Systems Technology (TCMD), Cryolife (CRY), Cerus (CERS), Orthopediatrics (KIDS), Intersect ENT (XENT), Orthofix Medical (OFIX), Anika Therapeutics (ANIK) and LeMaitre Vascular (LMAT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Anavex Life Sciences (AVXL), Sonoma Pharmaceuticals (SNOA), Opko Health (OPK), Novavax (NVAX), Advanced Micro Devices (AMD), POET Technologies (POETF), WPX Energy (WPX), Micron Technology (MU), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).

Inovio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (4.98%), Sumitomo Mitsui Trust Holdings Inc. (5.05%), ARK Investment Management LLC (4.58%), State Street Corp (1.56%), Geode Capital Management LLC (1.33%) and Jacobs Levy Equity Management Inc. (0.92%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Laurent Humeau, Peter Kies and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

INO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., TIAA FSB, Bank of New York Mellon Corp, Defender Capital LLC., Bank of America Corp DE and Credit Suisse AG. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner and Jong Joseph Kim. View Insider Buying and Selling for Inovio Pharmaceuticals.

INO stock was purchased by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., ARK Investment Management LLC, Renaissance Technologies LLC, California Public Employees Retirement System, Goldman Sachs Group Inc., Geode Capital Management LLC, UBS Group AG and Barclays PLC. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Jong Joseph Kim and Laurent Humeau. View Insider Buying and Selling for Inovio Pharmaceuticals.

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INO stock can currently be purchased for approximately $4.42.

Inovio Pharmaceuticals has a market capitalization of $448.01 million and generates $30.48 million in revenue each year. The biopharmaceutical company earns $-96,970,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. Inovio Pharmaceuticals employs 281 workers across the globe.View Additional Information About Inovio Pharmaceuticals.

The official website for Inovio Pharmaceuticals is http://www.inovio.com/.

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]